Key result
Current evidence supporting a genetic basis for drug-induced torsade de pointes arrhythmia is weak.
Why the study?
Does genetic predisposition explain drug-induced torsade de pointes arrhythmia?
Does genetic predisposition explain drug-induced torsade de pointes arrhythmia?
The current evidence supporting a genetic basis for drug-induced torsade de pointes is weak, suggesting other factors like pathology-based electrical remodeling may play a larger role.
Does not support genetic screening for drug-induced TdP risk; leaves open dominant contribution from non-genetic factors such as electrical remodeling.
Drug-induced torsade de pointes arrhythmia (TdP) is frequently seen in patients. This proarrhythmia is not restricted to anti-arrhythmics but includes a variety of drugs. A genetic predisposition is an attractive explanation for this clinical problem. In this review, we: 1) explain the arrhythmogenic mechanisms of TdP, 2) provide data for a genetic cause based upon mutations in the long QT or in cytochrome genes responsible for drug metabolism, and 3) present pathology-based electrical remodeling as an alternative explanation. It can be concluded that the current evidence for a genetic basis for drug-induced TdP is weak.
No takes yet. Share an insight, caveat, or question.
Vos et al. (2004) conducted a review in Drug-induced torsade de pointes arrhythmia (TdP). Genetic predisposition was evaluated on Drug-induced TdP. Current evidence supporting a genetic basis for drug-induced torsade de pointes arrhythmia is weak.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: